Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer.

Saved in:
Bibliographic Details
Title: Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer.
Authors: Elsayed L; Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE., Reed E; Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE., Modi S; Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE., Tandra PK; Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE., Copur MS; Mary Lanning Healthcare, Morrison Cancer Center, Department of Medicine, University of Nebraska Medical Center, Omaha, NE., Samson K; Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE., Krishnamurthy J; Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE. Electronic address: jairam.krishnamurthy@unmc.edu.
Source: Clinical breast cancer [Clin Breast Cancer] 2024 Dec; Vol. 24 (8), pp. 676-682.e1. Date of Electronic Publication: 2024 Jul 17.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0666
DOI:10.1016/j.clbc.2024.07.002